Dexcom Inc Stock Price, News & Analysis

Dexcom (DXCM) released its 'State of Type 2 Report' ahead of the ADA Scientific Sessions, revealing significant healthcare professional support for Continuous Glucose Monitoring (CGM) in Type 2 diabetes management. The report shows 59% of U.S. HCPs believe better CGM access will be most effective for diabetes management in the next decade. Notably, 96% support CGM as standard care for multiple daily insulin injections, and 100% recommend CGM with GLP-1 medications. The company will present clinical data at ADA 2025 demonstrating CGM benefits, including reduced mortality risk for insulin users and improved self-management for non-insulin users. Dexcom Warrior Lance Bass will share his experience with Dexcom G7 technology at the conference. The report also highlights that 60% of HCPs believe additional funding for CGM coverage could increase adoption among Type 2 diabetes patients.

Dexcom (NASDAQ: DXCM), a leader in real-time continuous glucose biosensing, has promoted Jake Leach to the role of president while maintaining his position as chief operating officer. Leach, who has over 21 years of leadership experience at Dexcom, has been instrumental in developing the company's biosensing platforms since their first commercial system launch.

In his COO role, which he has held since 2022, Leach oversees product development, global operations, R&D, quality management, regulatory and medical affairs. His expanded role as president will include additional oversight of Dexcom's corporate development and strategy efforts. CEO Kevin Sayer expressed strong confidence in Leach's ability to build upon his track record of innovation and achievement in metabolic health.

DexCom (DXCM) reported strong Q1 2025 financial results with revenue growing 12% year-over-year to $1.036 billion. The company saw U.S. revenue growth of 15% and international revenue growth of 7%. GAAP operating income reached $133.7 million, representing 12.9% of revenue.

Key developments include broader coverage with 2 of 3 largest PBMs now covering Dexcom CGM for diabetes patients, Stelo's launch on Amazon, and FDA clearance for the Dexcom G7 15 Day System. The company announced a $750 million share repurchase program and updated its 2025 guidance, projecting revenue of $4.60 billion (14% growth) with Non-GAAP Operating Margin of approximately 21%.

Dexcom (NASDAQ: DXCM) has announced the fourth season of Dexcom U, its unique Name, Image and Likeness (NIL) program for college athletes with diabetes. The program is launching its first nationwide search for new athletes to join its 2025 roster, with nominations open through May 23.

Selected athletes will join eight returning members at the Dexcom U Signing Day Camp this summer, hosted by Baltimore Ravens tight end Mark Andrews. Participants will receive access to Dexcom Continuous Glucose Monitoring (CGM) technology, exclusive events, and networking opportunities with collegiate and professional athletes.

The program aims to showcase athletes who manage diabetes while competing at high levels, using Dexcom G7 technology to monitor their glucose levels in real-time through smartphones and smartwatches. The selection committee will focus on candidates who can serve as role models and share inspiring stories with the next generation of youth athletes.

Dexcom (NASDAQ:DXCM) has received FDA clearance for its Dexcom G7 15 Day Continuous Glucose Monitoring System for people over 18 with diabetes in the United States. The new system boasts an impressive 15.5 days of wear time and superior accuracy with an overall MARD of 8.0%.

Key features include waterproof capability, direct Apple Watch connectivity, automated activity logging, and a 12-hour grace period for sensor replacement. The system also offers remote glucose sharing with caregivers and enhanced alert settings.

The company plans to launch Dexcom G7 15 Day in the second half of 2025 and is working with insulin pump partners to ensure compatibility with automated insulin delivery systems. Clinical data presented at the Advanced Technologies and Treatments for Diabetes conference in Amsterdam confirms G7 15 Day as the most accurate CGM for adults.

DexCom (NASDAQ:DXCM) has announced its upcoming first quarter 2025 earnings release and conference call schedule. The company will disclose its Q1 2025 financial results after market close on Thursday, May 1, 2025.

Management will host a conference call at 4:30 p.m. Eastern Time on the same day to discuss the quarterly performance. Investors can access the call by dialing (888) 414-4585 (US/Canada) or (646) 960-0331 (International) using confirmation ID '9430114'. A concurrent webcast will be available on the Dexcom investor relations website at investors.dexcom.com, where it will also be archived for future reference.

Dexcom (NASDAQ: DXCM) announces expanded public coverage for its continuous glucose monitoring (CGM) systems in Saskatchewan, Canada. The government's new coverage now includes young adults aged 18-25 and seniors over 65 who use any type of insulin, adding to existing coverage for ages 2-18.

The expansion, part of Budget 2025, will benefit nearly 10,000 individuals living with diabetes in the province. Dexcom's G7 and G6 CGM systems feature a predictive Urgent Low Soon alert that warns users up to 20 minutes before severe hypoglycemic events, helping prevent dangerous blood sugar levels below 3.1 mmol/L.

The systems integrate with various insulin pumps and digital health apps, including the Dexcom Follow app for remote monitoring by family members. This coverage expansion represents a significant advancement in diabetes care accessibility in Saskatchewan.

Dexcom (NASDAQ: DXCM), the global leader in glucose biosensing, has appointed Jon Coleman as Chief Commercial Officer. Coleman brings over 30 years of global commercial leadership experience and will oversee Dexcom's global commercial organization, including sales, marketing, and customer experience.

Coleman previously served as an executive officer at Masimo (NASDAQ: MASI) for 15 years, where he was president of commercial teams. He managed worldwide hospital sales, OEM, alternate care sales, clinical teams, and customer service. Prior to Masimo, Coleman held leadership positions at Pfizer (NYSE: PFE) Consumer Healthcare, including vice president and general manager of Canada and the Caribbean region, with additional experience in Asia and Latin America.

Throughout his career, Coleman has demonstrated success in scaling operations, developing innovative products, entering new markets, and delivering strong growth performance.

Dexcom (NASDAQ: DXCM) unveiled groundbreaking developments at ATTD 2025, including first-ever data for its G7 15 Day system showing an impressive 8.0% MARD, making it the most accurate CGM sensor available. The company also released a multi-region report surveying over 2,500 people across Europe and the Middle East.

Key findings from the report reveal that 52% of healthcare professionals favor CGM technology and education over medication for Type 2 diabetes management. The study showed 93% of CGM users reported positive impact, significantly exceeding pre-use expectations of 77%. Additionally, 96% of HCPs agreed CGM should be standard care for multiple daily insulin injection users.

Dexcom strengthened its position as the most connected CGM brand by announcing new integrations with Omnipod® 5 Automated Insulin Delivery System in multiple regions and direct connectivity with NovoPen® 6 and NovoPen Echo® Plus in Germany, with planned expansion to other markets.